Thanks @Quitman for that post.
With Relyvrio out of the way. Basically leaves ourselves v Riluzole and Radicava. Riluzole increases median survival by up to 19 months .
Radicava costs $145 K PY . Short half live. 6 months median survival . Folks, that is our opposition now. PAA are now in a unique situation of saying to BP this is what we want in $. That's my read.
Kpax
Amylyx class action Relyvrio
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.015(8.11%) |
Mkt cap ! $89.00M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.5¢ | 18.8¢ | $311.3K | 1.576M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 388155 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |